One of our clients published preclinical data on NASH-fibrosis on International Journal of Gastroenterology
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in International Journal of Gastroenterology by Enanta Pharmaceuticals, Inc.:
Title: “Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis”
EDP-305, selective and potent FXR agonist, treatment group showed marked improvement in hepatocyte ballooning with significant reduction in NAFLD Activity score when compared with the control group in the STAM™ mouse model.
Please let me know if you would like further information on this publication or our NASH-HCC model.